BioSpace News Archive

The healthcare industry is plagued by a range of pressing challenges ranging from managing patient data to maintaining the supply chain of drugs.

International medical imaging IT and cybersecurity company Sectra has signed a ten-year enterprise imaging contract with St. Claraspital in Basel, Switzerland.

BrainStorm Cell Therapeutics Inc. announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens on June 29, 2020.

Sana Biotechnology, Inc., focused on engineering cells as medicines for patients, announced the funding of all tranches of its initial financing, raising over $700 million.

Teleflex Incorporated, a leading global provider of medical technologies, announced an online submission portal for its COVID‑19 Humanitarian Product Donation Program.

One additional Phase 3 trial, along with previously completed Phase 2 trial, would be acceptable to support an efficacy claim for a New Drug Application filing

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that the Sana Klinikum Offenbach has entered into an agreement to lease and utilize a Senhance® Surgical System.

Virtual presentation will outline how leading organizations are using telemedicine to expand care access and improve patient transfer and treatment decisions [23-June-2020] SANDY, Utah , June 23, 2020 /PRNewswire/ -- Angie Franks, CEO of Central Logic , the healthcare industry’s innovator in patient orchestration and tools to accelerate access to care, will de

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced that the proposed resolution to elect Martha J. Demski to its Board of Directors was approved at the Company’s recent Annual Shareholder Meeting, held June 18, 2020.

Mateon Therapeutics, a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized, controlled, multi-center clinical study of OT-101.